WELCOME TO SR VAIDYA HOLISTIC WELLNESS RESEARCH INSTITUTE
Abstract
Obesity is a chronic, complex, relapsing disease and one of the fastest-growing public health challenges worldwide. In 2022, an estimated 1 in 8 people globally were living with obesity, including 890 million adults and 160 million children and adolescents, with worldwide adult obesity more than doubling since 1990 and adolescent obesity quadrupling over the same period (WHO, 2025).
This paper examines obesity from a holistic wellness perspective while maintaining the primacy of evidence-based diagnosis and appropriate medical care. It reviews global prevalence statistics, BMI classification, the multi-organ-system health consequences of obesity, diagnostic evaluation, red-flag presentations and modern management.
The paper proposes the SR VAIDYA Integrative Framework for Obesity Wellness Education, built on early screening, verified diagnosis, individualised lifestyle support and responsible Ayurvedic integration. Ayurvedic and Panchakarma approaches are discussed within clear safety boundaries as complementary wellness measures that must never replace or delay evidence-based diagnosis or treatment, including pharmacotherapy or bariatric surgery where clinically indicated.
Keywords: Obesity, Overweight, Body Mass Index, Weight Management, Metabolic Health, Holistic Wellness, Ayurveda, Panchakarma, Lifestyle Medicine, Integrative Health.
01 / Introduction
Introduction
Obesity has been formally recognised as a chronic, complex disease rather than simply a risk factor or lifestyle choice, reflecting growing scientific understanding of its biological, genetic, hormonal and environmental determinants.
The World Health Organization defines obesity as abnormal or excessive fat accumulation that presents a risk to health. The rise in global obesity prevalence has been described as a modern pandemic: worldwide adult obesity has more than doubled since 1990, and obesity among children and adolescents has quadrupled over the same period, with the trend now firmly established across low-, middle-, and high-income settings alike (WHO, 2025).
02 / Global Burden
Global Statistics and Epidemiological Scale
Reliable prevalence data are essential to appropriately scale awareness, clinical services and research investment. In 2022, 43% of adults aged 18 and over were classified as overweight and 16% as living with obesity.
Global Adult Weight Classification Breakdown
Figure 1. Global Obesity Burden in Numbers (WHO 2025, NCD-RisC 2024).
1 in 8
People globally living with obesity in 2022 (890M adults)
43%
Global adult population classified with overweight (BMI ≥ 25)
3.8 Billion
Projected adults with overweight/obesity worldwide by 2050
03 / Classification
Body Mass Index (BMI) Classification
Body Mass Index (BMI), calculated as weight in kilograms divided by height in metres squared (kg/m²), remains the primary population-level screening tool:
| Classification | BMI Range (kg/m²) | Risk of Comorbidities |
|---|---|---|
| Underweight | < 18.5 | Low (increased risk of other clinical issues) |
| Normal Weight | 18.5 – 24.9 | Average / Baseline |
| Overweight (Pre-obesity) | 25.0 – 29.9 | Increased |
| Obesity Class I | 30.0 – 34.9 | Moderate |
| Obesity Class II | 35.0 – 39.9 | Severe |
| Obesity Class III (Severe/Morbid) | ≥ 40.0 | Very Severe |
04 / Multi-Organ Impact
Health Consequences of Obesity Across Organ Systems
Obesity affects nearly every organ system through combined mechanical and metabolic-inflammatory pathways:
METABOLIC & CARDIOVASCULAR
Systemic Cardio-Metabolic
Type 2 diabetes, insulin resistance, hypertension, dyslipidemia, coronary artery disease, stroke, and MASLD (fatty liver disease).
MECHANICAL & STRUCTURAL
Musculoskeletal & Respiratory
Obstructive sleep apnea (OSA), obesity hypoventilation syndrome, osteoarthritis of weight-bearing joints, and gastroesophageal reflux (GERD).
ENDOCRINE & ONCOLOGY
Hormonal & Malignancy
PCOS, male hypogonadism, subfertility, and elevated risk of certain cancers (endometrial, breast, colorectal, and renal cell).
PSYCHOSOCIAL
Mental Health & Stigma
Depression, anxiety, body image distress, and weight-related social stigma creating major barriers to healthcare engagement.
05 / Diagnostics
Diagnostic Evaluation
A comprehensive evaluation goes beyond a single weight scale reading to assess total metabolic and cardiovascular risk:
| Assessment | Clinical Purpose |
|---|---|
| Body Mass Index (BMI) | Population-level screening classification of weight status |
| Waist Circumference & Waist-to-Hip Ratio | Assesses visceral/central adiposity and independent metabolic risk |
| Blood Pressure & Fasting Lipid Panel | Screens for hypertension, atherogenic dyslipidemia, and cardiovascular risk |
| Fasting Glucose / HbA1c | Screens for prediabetes and type 2 diabetes mellitus |
| Thyroid Function Tests (TSH) | Excludes hypothyroidism as a contributing endocrine factor |
| Sleep & Psychological Screening | Identifies obstructive sleep apnea, mood disorders, and disordered eating |
06 / Red Flags
Red Flag Presentations Requiring Urgent Assessment
Clinical Indicators Requiring Prompt Specialist Care
- Rapid, unintentional weight change (gain or loss) without clear lifestyle explanation — warrants evaluation for endocrine or malignant causes.
- Severe obesity (BMI ≥ 40) with uncontrolled comorbidities (uncontrolled diabetes, severe sleep apnea, or heart failure).
- Signs suggestive of severe obstructive sleep apnea (witnessed apneas, gasping, severe daytime somnolence) — requires urgent sleep study.
- Significant clinical depression, severe binge-eating disorder, or body image distress — mandates dedicated mental health support.
- Stigmata of secondary endocrine causes (e.g., Cushingoid features, severe hypothyroidism) — requires endocrine work-up.
07 / Stepped-Care Management
Modern Management of Obesity
Management follows an individualized, stepped-care model based on BMI class, comorbidities, and patient goals:
Foundational
Lifestyle Intervention
Structured dietary modification, physical activity, and behavioral therapy forming the foundation of care across all BMI classes.
Pharmacotherapy
GLP-1 & Incretin Therapies
GLP-1 receptor agonists and approved anti-obesity medications as powerful adjunctive treatments for eligible patients.
Metabolic Surgery
Bariatric Surgery
Considered for individuals with BMI ≥ 40 (or BMI ≥ 35 with significant comorbidities) following multidisciplinary evaluation.
Behavioral
Psychological Support
Addressing disordered eating patterns, emotional eating, and internalised weight stigma through cognitive-behavioral tools.
Long-Term
Ongoing Monitoring
Structured long-term follow-up to support weight maintenance, prevent weight regain, and optimize metabolic markers.
08 / Obesogenic Environment
The Psychological and Environmental Connection
Weight regulation is driven by neuroendocrine appetite signaling, genetics, and environment rather than willpower alone. Modern “obesogenic” environments (ubiquitous hyper-palatable, energy-dense foods and sedentary built environments) are major structural drivers of rising global prevalence.
09 / Ayurveda
Ayurvedic and Holistic Wellness Perspective
Ayurvedic classical texts classify obesity under Sthaulya or Medoroga, attributed to impaired metabolic fire (Agni) and excessive accumulation of Kapha and Meda Dhatu (adipose tissue). Traditional management focuses on Ahara (dietary correction), Vihara (lifestyle discipline), Vyayama (physical activity), and correction of metabolic sluggishness.
10 / Panchakarma
Panchakarma: The Need for Responsible Integration
Procedures historically used for metabolic management (such as structured Ahara, Udvartana herbal powder massage, and individualized mild Basti protocols) require clinical caution.
Clinical Boundaries
Panchakarma is contraindicated in unstable cardiovascular disease, uncontrolled diabetes, or severe untreated sleep apnea. It must never be promoted as a rapid weight-loss fix, a substitute for approved pharmacotherapy, or an alternative to indicated bariatric surgery.
11 / SR VAIDYA Framework
The SR VAIDYA Holistic Wellness Framework
A structured, sequential integrative framework for responsible obesity education and support:
S
SCREEN (BMI & Waist)
R
VERIFY (Metabolic Profile)
V
REFER (Endo / Bariatric)
A
SUPPORT (Sustainable Nutrition)
I
MONITOR (Vitals & Labs)
D
EDUCATE (Behavioral Habits)
Y-A
FOLLOW UP (Long-Term Care)
12 / Root-Factor Analysis
Root-Factor Analysis: A Scientifically Responsible Approach
Obesity is heterogeneous and multifactorial. Root-Factor Analysis evaluates the multi-system network shaping an individual's weight trajectory:
Genetic Risk
Neuroendocrine / Appetite
Dietary Patterns
Physical Inactivity
Sleep Disruption
Chronic Stress
Obesogenic Environment
Medication Factors
13 / Evidence
Evidence Grading of Key Claims
| Claim | Evidence Grade | Scientific Basis |
|---|---|---|
| ~1 in 8 people globally lived with obesity in 2022 (890M adults) | Strong | WHO Fact Sheet 2025; NCD-RisC Lancet global pooled analysis |
| Obesity is an independent risk factor for T2DM, CVD, and certain cancers | Strong | Extensive global epidemiological and mechanistic literature |
| GLP-1 receptor agonists produce clinically significant weight loss | Strong | Multiple large-scale phase III randomized clinical trials (STEP trials) |
| Bariatric surgery produces sustained weight loss and comorbidity remission | Strong | Extensive long-term prospective surgical outcomes data |
| Structured behavioral and dietary counselling improves weight maintenance | Moderate | Consistent trial evidence; effect sizes depend on programme intensity |
| Specific Ayurvedic herbal formulations produce weight loss comparable to drugs | Weak | Limited, heterogeneous studies; insufficient for drug substitution |
| Panchakarma alone produces sustained, clinically significant weight loss | Weak / Unsupported | No robust controlled evidence; not a substitute for standard therapy |
14 / Discussion
Discussion
The future of obesity care requires integration without exaggeration. Conventional medicine provides diagnostic precision, evidence-based pharmacotherapy, bariatric surgical options, and structured clinical support. Holistic wellness contributes sustainable dietary education, physical activity promotion, stress management, and a weight-stigma-free environment to support lifelong health.
15 / Recommendations
Proposed Conference Recommendations
1
Encourage comprehensive assessment (waist circumference, metabolic panel) alongside BMI rather than weight in isolation.
2
Train wellness practitioners to recognise red-flag presentations requiring urgent medical or endocrine referral.
3
Focus lifestyle interventions on sustainable behavioral change rather than claiming rapid or guaranteed weight-loss cures.
4
Adopt a weight-stigma-free, compassionate communication approach across all wellness and clinical settings.
5
Individualise Ayurvedic interventions and never delay pharmacotherapy or bariatric surgical evaluation where indicated.
6
Conduct ethically designed observational and controlled clinical studies of integrative wellness in obesity management.
7
Study quality of life, psychological wellbeing, and metabolic outcomes without unsupported rapid-weight-loss claims.
16 / Future Research
Future Research Proposal for SR VAIDYA
“Effect of a Structured Holistic Lifestyle and Behavioural Support Programme on Weight Maintenance and Quality of Life in Adults Receiving Standard Medical Care for Obesity.”
17 / Conclusion
Conclusion
Obesity is a major, rapidly growing global health concern affecting more than one in eight people worldwide. Managing the intricate relationship between genetics, neuroendocrine appetite regulation, environment, mental health, and daily lifestyle requires both precise medical management and sustained, compassionate lifestyle support.
SCREEN → VERIFY → REFER → SUPPORT → FOLLOW UP
Acknowledgement
Acknowledgement
The author acknowledges the importance of interdisciplinary dialogue between conventional medicine, endocrinology, bariatric surgery, psychology, Ayurveda, lifestyle medicine, and holistic wellness research in developing patient-centred and scientifically responsible approaches to obesity.
References
Key Scientific References
- World Health Organization. (2025). Obesity and overweight [Fact sheet]. WHO Press.
- NCD Risk Factor Collaboration (NCD-RisC). (2024). Worldwide trends in underweight and obesity from 1990 to 2022: A pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. The Lancet, 403(10431), 1027–1050.
- Wharton, S., et al. (2020). Obesity in adults: A clinical practice guideline. CMAJ, 192(31), E875–E891.
- Bray, G. A., Kim, K. K., & Wilding, J. P. H. (2017). Obesity: A chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Obesity Reviews, 18(7), 715–723.
- Wilding, J. P. H., et al. (2021). Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine, 384(11), 989–1002.
- Puhl, R. M., & Heuer, C. A. (2010). Obesity stigma: Important considerations for public health. American Journal of Public Health, 100(6), 1019–1028.
- Chooi, Y. C., Ding, C., & Magkos, F. (2019). The epidemiology of obesity. Metabolism, 92, 6–10.